GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Covidien PLC (FRA:6COP) » Definitions » Piotroski F-Score

Covidien (FRA:6COP) Piotroski F-Score : 7 (As of May. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Covidien Piotroski F-Score?

Good Sign:

Piotroski F-Score of 7 is 7, indicating very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Covidien has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Covidien's Piotroski F-Score or its related term are showing as below:

FRA:6COP' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Covidien was 8. The lowest was 4. And the median was 6.


Covidien Piotroski F-Score Historical Data

The historical data trend for Covidien's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covidien Piotroski F-Score Chart

Covidien Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 6.00 6.00 7.00

Covidien Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 4.00 6.00 7.00 7.00

Competitive Comparison of Covidien's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Covidien's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Covidien's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Covidien's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Covidien's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec14) TTM:Last Year (Dec13) TTM:
Net Income was 318.843 + 225.216 + 401.192 + 414.421 = €1,360 Mil.
Cash Flow from Operations was 557.433 + 180.32 + 601.4 + 365.761 = €1,705 Mil.
Revenue was 1878.354 + 1978.368 + 2121.584 + 2178.346 = €8,157 Mil.
Gross Profit was 1097.514 + 1165.824 + 1289.712 + 1333.284 = €4,886 Mil.
Average Total Assets from the begining of this year (Dec13)
to the end of this year (Dec14) was
(14321.87 + 14826.561 + 14884.128 + 16063.976 + 16718.765) / 5 = €15363.06 Mil.
Total Assets at the begining of this year (Dec13) was €14,322 Mil.
Long-Term Debt & Capital Lease Obligation was €3,285 Mil.
Total Current Assets was €4,531 Mil.
Total Current Liabilities was €2,364 Mil.
Net Income was 338.908 + 300.168 + 278.256 + 290.54 = €1,208 Mil.

Revenue was 1953.16 + 1954.124 + 1914.88 + 1926.47 = €7,749 Mil.
Gross Profit was 1179.616 + 1162.014 + 1112.276 + 1140.99 = €4,595 Mil.
Average Total Assets from the begining of last year (Dec12)
to the end of last year (Dec13) was
(16801.338 + 17454.92 + 15322.97 + 14898.664 + 14321.87) / 5 = €15759.9524 Mil.
Total Assets at the begining of last year (Dec12) was €16,801 Mil.
Long-Term Debt & Capital Lease Obligation was €3,662 Mil.
Total Current Assets was €4,263 Mil.
Total Current Liabilities was €1,624 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Covidien's current Net Income (TTM) was 1,360. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Covidien's current Cash Flow from Operations (TTM) was 1,705. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec13)
=1359.672/14321.87
=0.09493676

ROA (Last Year)=Net Income/Total Assets (Dec12)
=1207.872/16801.338
=0.07189142

Covidien's return on assets of this year was 0.09493676. Covidien's return on assets of last year was 0.07189142. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Covidien's current Net Income (TTM) was 1,360. Covidien's current Cash Flow from Operations (TTM) was 1,705. ==> 1,705 > 1,360 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec13 to Dec14
=3285.361/15363.06
=0.21384809

Gearing (Last Year: Dec13)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec12 to Dec13
=3661.68/15759.9524
=0.2323408

Covidien's gearing of this year was 0.21384809. Covidien's gearing of last year was 0.2323408. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec14)=Total Current Assets/Total Current Liabilities
=4531.057/2364.065
=1.91663808

Current Ratio (Last Year: Dec13)=Total Current Assets/Total Current Liabilities
=4263.2/1624.25
=2.6247191

Covidien's current ratio of this year was 1.91663808. Covidien's current ratio of last year was 2.6247191. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Covidien's number of shares in issue this year was 458. Covidien's number of shares in issue last year was 456. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4886.334/8156.652
=0.59906123

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4594.896/7748.634
=0.59299433

Covidien's gross margin of this year was 0.59906123. Covidien's gross margin of last year was 0.59299433. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec13)
=8156.652/14321.87
=0.56952423

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec12)
=7748.634/16801.338
=0.46119148

Covidien's asset turnover of this year was 0.56952423. Covidien's asset turnover of last year was 0.46119148. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Covidien has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Covidien  (FRA:6COP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Covidien Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Covidien's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Covidien (FRA:6COP) Business Description

Traded in Other Exchanges
N/A
Address
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.

Covidien (FRA:6COP) Headlines

No Headlines